

Investor Call and renewal of ISO 13485 certification

Perth, Australia & Malta – *9 November 2017* – Neurotech International Limited (ASX: NTI) ("Neurotech" or the "Company"), developer of quality medical solutions in the neuroscience space, concluded an investor call on 8 November 2017. The recording of the investor call is available - http://mentetech.com/wp-content/uploads/2017/11/NTI%20Conference%20Call.mp4.

Neurotech's Malta-based subsidiary, AAT Medical, has also successfully renewed its ISO 13485:2012 certification in early November. The ISO certification relates to meeting requirements and standards to design, manufacture and service therapeutic neurological, active medical devices and was conducted by ITALCERT.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

http://www.neurotechinternational.com. http://www.mentetech.com.

For more information please contact:

Matthew Wright matt@nwrcommunications.com.au

Tel: +61 451 896 420